Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy
Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read MoreTop Stories
Biopharma Trends 2025: 3 Things to Know Right Now
The global business climate is ever-evolving, and 2025 looks...
Science, AI, and Human Ingenuity Converge to
Today, we're witnessing an unprecedented convergence of...
The Paradigm Shift from Traditional Scientific
In the rapidly evolving biopharma landscape, the approach to...
Filter
The Business Case for Diversity, Equity, and Inclusion (DE&I) in the Pharma Industry
To learn how much businesses can gain from more diverse and inclusive workplaces and why...
Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy
Read this update on how the New England Journal of Medicine is trying to promote...
Pharma, Physician, and Patient Pain Points Regarding Clinical Trials
Pharma, physicians, and patients consistently face challenges related to clinical trials. Here's a quick look...
Clinical Trial Summaries – What Are They and Why Do They Matter for Pharma?
A majority of patients feel lay summaries for clinical trials are very important and won’t...
How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications
A roadmap on how to drive advocacy for EDI in medical communications and publications and...
3 Factors That Will Help Pharma Build Public Trust
Pharma must engage with patients at all levels to build public trust...
- 1
- 2